Results 121 to 130 of about 89,071 (292)
Exercise‐induced dynamic mitral regurgitation is associated with outcomes in patients with ischaemic cardiomyopathy
ESC Heart Failure, EarlyView.Abstract Aims
Ischaemic mitral regurgitation (MR) is a dynamic condition influenced by global and regional left ventricular remodelling as well as mitral valvular deformation. Exercise testing plays a substantial role in assessing the haemodynamic relevance of MR and is recommended by current guidelines.Maximilian Spieker, Jonas Sidabras, Hannah Lagarden, Lucas Christian, Niklas Günther, Stephan Angendohr, Alexandru Bejinariu, P. Christian Schulze, Roman Pfister, Can Öztürk, Ralf Westenfeld, Patrick Horn, Amin Polzin, Malte Kelm, Obaida Rana +14 morewiley +1 more sourceClinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
European Journal of Heart Failure, Volume 24, Issue 11, Page 2131-2139, November 2022., 2022 Among patients with new‐onset or worsening heart failure (HF) undergoing optimization of HF medical therapy, dose up‐titration of angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) therapy was associated with lower likelihood of left atrial adverse remodelling (LAAR).Riccardo M. Inciardi, Matteo Pagnesi, Carlo M. Lombardi, Stefan D. Anker, John G. Cleland, Kenneth Dickstein, Gerasimos S. Filippatos, Chim C. Lang, Leong L. Ng, Pierpaolo Pellicori, Piotr Ponikowski, Nilesh J. Samani, Faiez Zannad, Dirk J. van Veldhuisen, Scott D. Solomon, Adriaan A. Voors, Marco Metra +16 morewiley +1 more sourceBLITZ‐HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines
European Journal of Heart Failure, Volume 24, Issue 11, Page 2078-2089, November 2022., 2022 Aims
To assess adherence to guideline recommendations among a large network of Italian cardiology sites in the management of acute and chronic heart failure (HF) and to evaluate if an ad‐hoc educational intervention can improve their performance on several pharmacological and non‐pharmacological indicators.Michele Massimo Gulizia, Francesco Orso, Andrea Mortara, Donata Lucci, Nadia Aspromonte, Leonardo De Luca, Giuseppe Di Tano, Giuseppe Leonardi, Alessandro Navazio, Giovanni Pulignano, Furio Colivicchi, Andrea Di Lenarda, Fabrizio Oliva, on behalf of
BLITZ‐HF Investigators, G. Pajes, A.R. Felici, P. Midi, G. Leonardi, G. Montana, V. Randazzo, E. Guerri, E. Lo Jacono, V. Zanasi, C. Leuzzi, V. Rizzello, A. Battagliese, N. Pagnoni, G. Pulignano, M. Uguccioni, M.D. Tinti, G.M. Frigo, M. Anselmi, E. Zorzi, I. Battistoni, G.P. Perna, L. Prosseda, M. Pulcini, C. Pellizzari, C. Paolini, G. Bardelli, R. Panciarola, B. Bordoni, S. Urbinati, C. Pedone, C. Greco, E.R. Cosentino, C. Borghi, C. Cuccia, L. Caprini, C. Mariani, C. Borghi, E. Benvenuto, M.B. Zisa, G.M. Francese, M.M. Gulizia, M. Bartolotti, M. Marconi, D. Severini, K. Mboumi, E. Capati, F. Venturi, E. Savini, D. Gabrielli, A. Herbst, F. Orso, F. Sani, C. Minneci, E. Gardini, D. Nanni, C. Lirato, F. Piemonte, P. Ameri, M. Canepa, F. Mainardi, R. Ghinazzi, F. Poletti, C. Inserra, S. Arcidiacono, V. Crisci, C.C. De Carlini, S. Maggiolini, F. Napoli, A.G. Versace, I. Di Matteo, A. Sacco, A.F. Giglio, M.G. Cipriani, G. Mombelli, A. Alberti, V. Antonazzo, O. Agostoni, G. Riboni, G. Guazzotti, S. Mazzetti, A. Mortara, L. Montagna, M.G. Perrelli, L. Scelsi, S. Ghio, A. Gualco, C. Opasich, L. Filippucci, A. Burini, I. Puggia, E. Loiudice, G. Iabichella, A. Nicosia, A. Frisinghelli, G. De Angelis, P. Del Corso, F. Marzo, S. Carigi, G. Piovaccari, S. Refice, T. Nejat, S.A. Di Fusco, F. Colivicchi, D. Pini, P. Romano, G. Padula, A. Gigantino, L. Spera, A. Pagliaro, L.L. Piccioni, C. Napoletano, C. Calcagnile, P. Sbarra, D. Belloli, P.C. Sganzerla, M. Merlo, V. De Paris, M. Driussi, D. Miani, C.A. Gianonatti, L. Moretti, G. Licciardello, V. Palmieri, P. Costa, S. Zingaro, L. Tedesco, A. Iacovoni, M. Liotino, A. Ravera, A. De Castro, G. Rossetti, M. Corda, D. Armata, G. Vianello, E. Pelissero, G. Ruberti, S. D'Orazio, C. Pedrinazzi, D. Robba, A. Carbone, F. De Cian, A. Fucili, F. Grossi, N.D. Brunetti, C. Minoia, M. Pernigo, S. Costa, L. Esposito, G. Senatore, P. Pelaggi, R. Poddighe, E. Zanelli, L. Salvini, G. Galati, A. Zanocco, M. Cannillo, A. Vincenzi, M.A. Losi, L. Caliendo, V. Orrù, E. Carluccio, L. Garritano, E. Garelli, R. Poletti, M. Taglioli, G. Scopelliti, M. Lo Presti, C. Gardini, S. Iosi, C. Tota, M. Mancone, C. De Matteis, F. Rusconi, M.A. Ammirati, G. Cicia, S. Meloni, F. Menozzi, A. Cafro, M. Ribezzo, I. Parrini, S. Giacomelli, G. Russo, F. Morandi, F. Sturniolo +197 morewiley +1 more sourceUse of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence
European Journal of Heart Failure, Volume 24, Issue 11, Page 2185-2195, November 2022., 2022 Patients with heart failure and chronic kidney disease are less likely to receive and persist on guideline‐recommended medical therapies. Aim
Half of heart failure (HF) patients have chronic kidney disease (CKD) complicating their pharmacological management.Roemer J. Janse, Edouard L. Fu, Ulf Dahlström, Lina Benson, Bengt Lindholm, Merel van Diepen, Friedo W. Dekker, Lars H. Lund, Juan‐Jesus Carrero, Gianluigi Savarese +9 morewiley +1 more source